Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia

Ethics approval and consent to participate

Blood samples were obtained from CLL patients at The Ohio State University, who consented to an Institutional Review Board–approved tissue procurement protocol or who were enrolled in Institutional Review Board–approved clinical trial of nemtabrutinib in CLL. All patients gave written informed consent in accordance with the Declaration of Helsinki. All animal protocols were reviewed and approved by The Ohio State University Institutional Animal Care and Use Committee.

Consent for publication

Not applicable.

Availability of data and materials

The data that support the findings of this study are available on request from the corresponding author.

Competing interests

JCB reports consulting, stock ownership with Vincerx, consulting with AstraZeneca, Syndax, Janssen, Pharmacyclics, Acerta, and Trillium that are outside of the submitted work. JAW has consulted for Abbvie, AstraZeneca, Beigene, Genentech, Janssen, Loxo, Newave, Pharmacyclics, and Schrodinger and receives research funding from Abbvie, Janssen, Morphosys, and Schrodinger. KAR receives research funding from Genentech, AbbVie, Novartis, and Janssen, consults for AstraZeneca, Beigene, Genentech, AbbVie, Pharmacyclics, and Innate Pharma and received travel funding from AstraZeneca. DS has received honoraria from Newave.

留言 (0)

沒有登入
gif